DISCLOSURES

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), the National Foundation for Infectious Diseases (NFID) must ensure balance, independence, objectivity, and scientific rigor in continuing medical education activities. NFID takes responsibility for the content, quality, and scientific integrity of this Continuing Medical Education (CME) activity.

All individuals in a position to control the content of a continuing medical education activity are required to disclose all relevant financial relationships with any ACCME-defined commercial interests for themselves and/or spouse/partner for the past 12 months. Disclosure information is reviewed in advance to manage and resolve any real or perceived conflict of interest that may affect the balance and scientific integrity of an educational presentation.

For details of NFID policies on managing conflicts of interest, visit www.nfid.org/coi.

- Carol J. Baker (Invited Speaker) serves as an advisor or consultant for Pfizer Inc.
- Marla Dalton (NFID Staff) owns stock, stock options, patent(s), or other intellectual property from Merck & Co., Inc.
- Janet A. Englund (Invited Speaker) serves as an advisor or consultant for Meissa Vaccines, Inc. and Sanofi Pasteur, received grants or other research support from AstraZeneca, GlaxoSmithKline, Merck & Co., Inc., and Novavax, Inc.
- Harry B. Greenberg (Invited Speaker) serves as an advisor or consultant for Aridis Pharmaceuticals, Inc., Dynavax Technologies Corporation, FluGen Inc., Pfizer Inc., and Sanofi Pasteur.
- Nicola P. Klein (ACVR Planning Committee) received grants or other research support from GlaxoSmithKline, Merck & Co., Inc., Pfizer Inc., Protein Sciences, and Sanofi Pasteur
- Camille N. Kotton (Invited Speaker) serves as an advisor or consultant for GlaxoSmithKline, Hookipa Pharma Inc., ResTorBio
- J. Christopher Love (Invited Speaker) serves as an advisor or consultant and owns stock, stock options, patent, or other intellectual property from Sunflower Therapeutics (self and spouse)
- Gregory A. Poland (ACVR Executive Planning Committee) serves as an advisor or consultant for Adjuvance Technologies, Avianax, Dynavax Technologies Corporation, Emergent Biosolutions, GlaxoSmithKline, Medicago, Merck & Co., Inc., and Sanofi Pasteur
- William Schaffner (NFID Medical Director, ACVR Executive Planning Committee) serves as an advisor or consultant for Merck & Co., Inc., Pfizer Inc., and Roche Diagnostics
- H. Keipp B. Talbot (NFID Director, ACVR Executive Planning Committee) serves as an advisor or consultant for Seqirus

All other speakers, activity planners/reviewers, and staff for this activity have no relevant financial relationships to disclose (as of 06/15/2020).